文献速递瓣膜外科

血液透析患者机械瓣与生物瓣的选择比较

Mechanical versus bioprosthetic heart valves in patients on hemodialysis.
PubMed 文献 · J Thorac Cardiovasc Surg · 2025-12-24

本研究基于韩国国民健康保险共享服务数据库765例首次瓣膜置换的血液透析患者,比较生物瓣(421例)与机械瓣(344例)的临床结局。校正后两组早期结局及晚期死亡率相当,生物瓣组再行主动脉瓣置换更频繁,机械瓣组胃肠道出血更常见,各年龄亚组生存无显著差异,估计中位生存时间随年龄增长而缩短。

要点

  • 血透患者瓣膜置换后中位生存期短,生物瓣可能是年轻患者的合理选择。
  • 生物瓣组再行主动脉瓣置换率高于机械瓣组,机械瓣组胃肠道出血更常见。
  • 两组各年龄亚组生存无显著差异,高钙血症或肾移植候选者除外。

核心结论

  • 鉴于血透患者寿命显著缩短,生物瓣可能是年轻患者的合理选择,但高钙血症或潜在肾移植候选者除外。

研究设计与样本

  • 回顾性队列研究,从韩国国民健康保险共享服务数据库提取765例首次瓣膜置换的血液透析患者,生物瓣组421例,机械瓣组344例。

主要发现

  • 校正后两组早期临床结局和晚期死亡率相当。
  • 生物瓣组再行主动脉瓣置换发生率高于机械瓣组(1.3%/患者年 vs 0.3%/患者年;P = .002)。
  • 机械瓣组胃肠道出血发生率高于生物瓣组(7.0%/患者年 vs 4.8%/患者年;P = .010)。
  • 各年龄依赖亚组两组生存无显著差异。
  • 估计中位生存时间:<50岁为6.6年,50-64岁为4.0年,≥65岁为2.1年。

关键数值与推荐

  • 竞争风险分析显示机械瓣与较低的再行主动脉瓣置换发生率相关(校正亚分布风险比0.24 [0.09-0.66];P = .006)。
  • 竞争风险分析显示机械瓣与较高的主要出血事件发生率相关(校正亚分布风险比1.46 [1.13-1.89];P = .004)。

临床怎么用

  • 血透患者瓣膜选择需权衡再手术风险与出血风险,年轻患者可考虑生物瓣,但高钙血症或肾移植候选者除外。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Appropriate valve selection in patients on hemodialysis requiring valve replacement is a highly contentious issue because of these patients' short life expectancy and accelerated deterioration of bioprosthetic valves. This study aims to analyze clinical outcomes on the basis of the types of prosthetic valves and to estimate life expectancy and valve durability in this cohort. METHODS: In total, 765 patients on hemodialysis undergoing first-time valve replacement were extracted from the Korean National Health Insurance Sharing Service database. Clinical outcomes were compared between the bioprosthetic (n = 421) and mechanical (MP; n = 344) valve groups. An age-dependent subgroup analysis was conducted, and the median survival time was calculated. A competing risk analysis for late clinical events was also performed. RESULTS: After adjustment, the early clinical outcomes and late mortality were comparable between the 2 groups. Redo aortic valve replacements (AVRs) occurred more frequently in the bioprosthetic group (1.3%/patient-year vs 0.3%/patient-year; P = .002), whereas gastrointestinal bleeding was more common in the MP group (7.0%/patient-year vs 4.8%/patient-year; P = .010). The 2 groups did not show significant survival differences in all age-dependent subgroups. The estimated median survival times were 6.6, 4.0, and 2.1 years for patients aged <50, 50-64, and ≥65 years, respectively. Competing risk analysis showed a lower prevalence of redo AVRs and a greater prevalence of major bleeding events with MP use (adjusted subdistribution hazard ratio, 0.24 [0.09-0.66]; P = .006 and 1.46 [1.13-1.89]; P = .004). CONCLUSIONS: Given the considerably short lifespan of patients on hemodialysis, bioprosthetic valves may be a reasonable option for younger patients, except for those with hypercalcemia or potential candidates for kidney transplantation.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Ro SK, Kim J, Ryu S, et al. Mechanical versus bioprosthetic heart valves in patients on hemodialysis. J Thorac Cardiovasc Surg. 2025. PMID: 41453428. doi:10.1016/j.jtcvs.2025.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。